Skip to content
value.today

Ambit Biosciences Corp.

Formerly Aventa Biosciences Corporation

Total raised
$85 M
6 rounds on record
Latest round
$22 M
Oct 2012
First round on record
Jun 2009
Today
Private
No later event on record

Funding rounds

6 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Ambit Biosciences Corp.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2012$22 MNo. 6$10 to $50 million

Ambit Biosciences Corp.: Raise no. 6, Oct 2012

Investors in this round

16 investors had bought by the notice of Nov 9, 2012: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Ambit Biosciences Corp. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$22 M of $45 M offered; $23 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alan M. Fuhrman · Executive Officer
  • Athena M. Countouriotis · Executive Officer
  • Michael A. Martino · Executive Officer, Director
  • Allan M. Marchington · Director
  • David P. Bonita · Director
  • Faheem M. Hasnain · Director
  • Isai M. Peimer · Director
  • Joseph M. Regan · Director
  • Saiid M. Zarrabian · Director
  • Standish M. Fleming · Director
  • Steven A. Elms · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Alan Fuhrman, Chief Financial Officer. Source: SEC Form D, newest notice filed Nov 9, 2012. Read the notice at the SEC.

equity, optionsSEC
May 2012$7 MNo. 5$2 to $10 million

Ambit Biosciences Corp.: Raise no. 5, May 2012

Investors in this round

16 investors had bought by the notice of May 30, 2012: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Ambit Biosciences Corp. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$7 M of $11 M offered; $4 M still to sell
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alan M. Fuhrman · Executive Officer
  • Athena M. Countouriotis · Executive Officer
  • Michael A. Martino · Executive Officer, Director
  • Allan M. Marchington · Director
  • Faheem M. Hasnain · Director
  • Isai M. Peimer · Director
  • Joseph M. Regan · Director
  • Saiid M. Zarrabian · Director
  • Standish M. Fleming · Director
  • Steven A. Elms · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Alan Fuhrman, Chief Financial Officer. Source: SEC Form D, newest notice filed May 30, 2012. Read the notice at the SEC.

optionsSEC
May 2011$22 MNo. 4$10 to $50 million

Ambit Biosciences Corp.: Raise no. 4, May 2011

Investors in this round

20 investors had bought by the notice of Jul 11, 2011: 20 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Ambit Biosciences Corp. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$22 M of $30 M offered; $8 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alan J. Fuhrman · Executive Officer
  • Alan J. Lewis, Ph.D. · Executive Officer, Director
  • Christopher J. Morl · Executive Officer
  • Allan M. Marchington · Director
  • Faheem J. Hasnain · Director
  • Isai J. Peimer · Director
  • Joseph J. Regan · Director
  • Saiid J. Zarrabian · Director
  • Standish M. Fleming · Director
  • Steven J. Elms · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Includes $26,583.86 receivable by the Comp. upon the exercise of Warrants to purchase up to 26,583,858 shares of Company's Series D-2 Preferred Stock at a purchase price of $0.001, assuming no cashless exercise. Such Warrants have not yet been exercised.”

Signed by Alan Fuhrman, Chief Financial Officer. Source: SEC Form D, newest notice filed Jul 11, 2011. Read the notice at the SEC.

equity, optionsSEC
Sep 2010$15 MNo. 3$10 to $50 million

Ambit Biosciences Corp.: Raise no. 3, Sep 2010

Investors in this round

18 investors had bought by the notice of Oct 15, 2010: 18 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Ambit Biosciences Corp. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$15 M of $16 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alan J. Lewis, Ph.D. · Executive Officer, Director
  • Christopher J. Morl · Executive Officer
  • Wendell J. Wierenga, Ph.D. · Executive Officer
  • Alexander J. Zukiwski · Director
  • Allan M. Marchington · Director
  • Joseph J. Regan · Director
  • Saiid J. Zarrabian · Director
  • Standish M. Fleming · Director
  • Steven J. Elms · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Includes $912,976.68 receivable by the Company upon the exercise of Warrants to purchase up to 592,842 shares of Company's Common Stock at a purchase price of $1.54, assuming no cashless exercise. Such Warrants have not yet been exercised.”

Signed by Christopher J. Morl, Chief Business Officer. Source: SEC Form D, newest notice filed Oct 15, 2010. Read the notice at the SEC.

debt, optionsSEC
Mar 2010$12 MNo. 2$10 to $50 million

Ambit Biosciences Corp.: Raise no. 2, Mar 2010

Investors in this round

2 investors had bought by the notice of Apr 15, 2010: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Ambit Biosciences Corp. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$12 M of $13 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alan J. Lewis, Ph.D. · Executive Officer, Director
  • Kerry A. Kelly, J.D. · Executive Officer
  • Wendell J. Wierenga, Ph.D. · Executive Officer
  • Alexander J. Zukiwski · Director
  • Allan M. Marchington · Director
  • Joseph J. Regan · Director
  • Saiid J. Zarrabian · Director
  • Standish M. Fleming · Director
  • Steven A. Elms · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Includes amount receivable upon the exercise of Warrants to purchase i) up to 284,584 shares of Series D Preferred Stock at purchase price of $5.06 or ii) up to an undetermined number of shares of preferred stock at an undetermined purchase price.”

Signed by Kerry A. Kelly, J.D., Vice President and General Counsel. Source: SEC Form D, newest notice filed Apr 15, 2010. Read the notice at the SEC.

debt, optionsSEC
Jun 2009$6 MNo. 1$2 to $10 million

Ambit Biosciences Corp.: Raise no. 1, Jun 2009

Investors in this round

13 investors had bought by the notice of Jun 29, 2009: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Ambit Biosciences Corp. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$6 M of $20 M offered; $13 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • M. Scott Salka · Executive Officer, Director
  • Wendell Wierenga, Ph.D. · Executive Officer
  • Alan J. Lewis, Ph.D. · Director
  • Alexander Zukiwski · Director
  • Allan Marchington · Director
  • Saiid Zarrabian · Director
  • Standish M. Fleming · Director
  • Steven Elms · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “*Includes approximate amounts receivable by the Company upon the exercise of Warrants to purchase up to 2,039,521 shares of the Company's Common Stock at a purchase price of $0.91, assuming no cashless exercise. Such Warrants have not yet been exercised.”

Signed by M. Scott Salka, Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 29, 2009. Read the notice at the SEC.

debt, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Ambit Biosciences Corp. chose not to state its revenue in its newest notice of a funding round (Nov 2012).

    SEC Form D · Nov 2012

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Nov 2012

That is all the official record says: Ambit Biosciences Corp. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: its website does not describe any in structured form (a page that declares itself a product or service), and Wikidata lists none.

Investors#

2 named in official filings. Open an investor to see everything it has backed.

Investors in Ambit Biosciences Corp.
InvestorKindAmountRoundRoleSource
Orbimed Advisors LLCFund or asset managernot statednot statedHeld Series D, D-2 and E preferred stock, 10% owner (Form 3, 2013)SEC Form 3
OrbiMed Capital GP III LLCFund or asset managernot statednot statedHeld Series D, D-2 and E preferred stock, 10% owner (Form 3, 2013)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 6 rounds above had up to 20 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Ambit Biosciences Corp.
NameRoleNamed in
Alan M. FuhrmanExecutive officerNov 2012
Athena M. CountouriotisExecutive officerNov 2012
Michael A. MartinoExecutive officerNov 2012
Alan J. FuhrmanExecutive officerJul 2011
Alan J. Lewis, Ph.D.Executive officerJul 2011
Christopher J. MorlExecutive officerJul 2011
Wendell J. Wierenga, Ph.D.Executive officerOct 2010
Kerry A. Kelly, J.D.Executive officerApr 2010
M. Scott SalkaExecutive officerJun 2009
Wendell Wierenga, Ph.D.Executive officerJun 2009
Allan M. MarchingtonDirectorNov 2012
David P. BonitaDirectorNov 2012
Faheem M. HasnainDirectorNov 2012
Isai M. PeimerDirectorNov 2012
Joseph M. ReganDirectorNov 2012
Michael A. MartinoDirectorNov 2012
Saiid M. ZarrabianDirectorNov 2012
Standish M. FlemingDirectorNov 2012
Steven A. ElmsDirectorNov 2012
Alan J. Lewis, Ph.D.DirectorJul 2011
Faheem J. HasnainDirectorJul 2011
Isai J. PeimerDirectorJul 2011
Joseph J. ReganDirectorJul 2011
Saiid J. ZarrabianDirectorJul 2011
Steven J. ElmsDirectorJul 2011
Alexander J. ZukiwskiDirectorOct 2010
Alexander ZukiwskiDirectorJun 2009
Allan MarchingtonDirectorJun 2009
M. Scott SalkaDirectorJun 2009
Saiid ZarrabianDirectorJun 2009
Steven ElmsDirectorJun 2009

About

Company.